REGENXBIO Inc. Quarterly Costs and Expenses in USD from Q1 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
REGENXBIO Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2014 to Q2 2024.
  • REGENXBIO Inc. Costs and Expenses for the quarter ending June 30, 2024 was $78.3M, a 15.8% decline year-over-year.
  • REGENXBIO Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $338M, a 7.46% decline year-over-year.
  • REGENXBIO Inc. annual Costs and Expenses for 2023 was $358M, a 4.59% decline from 2022.
  • REGENXBIO Inc. annual Costs and Expenses for 2022 was $376M, a 21% increase from 2021.
  • REGENXBIO Inc. annual Costs and Expenses for 2021 was $310M, a 13.4% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $338M $78.3M -$14.8M -15.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $353M $79.5M -$5.81M -6.81% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $358M $86.1M -$3M -3.37% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $361M $93.9M -$3.68M -3.78% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $365M $93.1M -$2.1M -2.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $367M $85.3M -$8.45M -9.01% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $376M $89.1M +$4.06M +4.77% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $372M $97.6M +$9.44M +10.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $362M $95.2M +$20.9M +28.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $341M $93.7M +$30.8M +49% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $310M $85.1M +$9.96M +13.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $300M $88.1M +$3.16M +3.72% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $297M $74.3M +$15.9M +27.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $281M $62.9M +$7.58M +13.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $274M $75.1M +$23M +44.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 $251M $85M +$34.4M +67.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $216M $58.4M +$13.6M +30.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $203M $55.3M +$18.6M +50.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $184M $52.1M +$13.8M +35.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 $170M $50.6M +$22.6M +80.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 $148M $44.8M +$11.1M +32.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 $137M $36.8M +$6.42M +21.2% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 $130M $38.3M +$19.7M +106% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 $111M $28M +$5.39M +23.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 $105M $33.7M +$12.1M +55.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 $93.3M $30.4M +$6.99M +29.9% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 $86.3M $18.6M -$3.53M -15.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $89.8M $22.6M +$3.85M +20.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 $86M $21.6M +$4.29M +24.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 $81.7M $23.4M +$11.7M +101% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 $69.9M $22.2M +$12.2M +123% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-06
Q3 2016 $57.7M $18.8M +$10.3M +121% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-06
Q2 2016 $47.4M $17.3M +$9.67M +126% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-06
Q1 2016 $37.7M $11.6M +$7.01M +151% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-06
Q4 2015 $30.7M $9.94M +$6.58M +195% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-07
Q3 2015 $24.1M $8.49M +$6.3M +289% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-07
Q2 2015 $17.8M $7.66M +$5.51M +256% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-07
Q1 2015 $12.3M $4.64M +$2.54M +121% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-07
Q4 2014 $9.8M $3.37M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-03
Q3 2014 $2.18M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-03
Q2 2014 $2.15M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-03
Q1 2014 $2.1M Jan 1, 2014 Mar 31, 2014 10-K 2016-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.